Isoflurane sedation does not cut mortality in hypoxemic respiratory failure

The SAVE-ICU trial, a multicenter randomized trial across 14 Canadian ICUs, compared isoflurane-based inhaled sedation with intravenous adjuncts to usual intravenous sedation in 780 mechanically ventilated adults with acute hypoxemic respiratory failure. The trial reported no difference in hospital mortality between groups (42.5% vs 43.8%), and found the inhaled sedation group received more adjunctive therapies for hypoxemia and had fewer delirium- and coma-free days, with similar quality-of-life and disability outcomes at 3 months.

Most relevant for: Mechanically ventilated adults with acute hypoxemic respiratory failure, including non-COVID and COVID-19 related cases, managed in intensive care units.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.